Indicate by check mark whether the registrant files or will
file annual reports under cover of Form 20-F or Form 40-F:
Ridgetech, Inc., a Cayman Islands
exempted company furnishes under the cover of Form 6-K the following:
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
Exhibit 99.1
Ridgetech, Inc. Reports Fiscal Year 2026 Financial
Results
HANGZHOU, China, July 31, 2026 /PRNewswire/
-- Ridgetech, Inc. (Nasdaq: RDGT) (“Ridgetech” or the “Company”), a wholesale distributor of pharmaceutical
and other healthcare products in China, today announced its financial results for the fiscal year ended March 31, 2026.
Mr. Frank Zhao, Interim Chief Executive Officer
and Chief Financial Officer of Ridgetech, commented, “Fiscal year 2026 marked a transformative year for Ridgetech as we completed
our strategic transition to a wholesale-focused business model. Through the acquisition of Allright (Hangzhou) Internet Technology Co.
Ltd (“Allright”) and the divestiture of our retail drugstore business, we have strengthened our position as an online and
offline wholesale distributor of pharmaceutical and healthcare products, establishing a more scalable and efficient operating platform.
“Our revenue increased 10.2% year over year
to $132.2 million, driven primarily by the first full year contribution from Allright’s online platform business. We also delivered
a 23.8% increase in gross profit and improved our overall gross margin to 3.6%, reflecting the benefits of our optimized business mix
and continued operational execution.
“Today, our business combines a strong offline
wholesale network serving local customers with expanding nationwide online distribution through both our proprietary platform and leading
third-party e-commerce platforms. We believe this integrated online and offline model enhances our market reach, broadens our customer
base, and positions us to capture long-term opportunities in China’s pharmaceutical distribution market.
“Looking ahead, we remain focused on executing
our dual-engine growth strategy by expanding our digital distribution capabilities, strengthening our pharmaceutical ecosystem, and pursuing
strategic initiatives that enhance operational efficiency and create long-term value for our shareholders.”
Fiscal Year 2026 Financial Summary
| ● | Revenue
was $132.16 million for the fiscal year ended March 31, 2026, an increase of 10.2% from $119.97 million for
the same period of last year. |
| ● | Gross profit was $4.75 million for
the fiscal year ended March 31, 2026, an increase of 23.8% from $3.84 million for the same period of last year. |
| ● | Gross margin was 3.6% for the fiscal year ended March
31, 2026, an increase from 3.2% for the same period of last year. |
| ● | Net loss was $1.25 million, or $17.21 per
basic and diluted loss per share, for the fiscal year ended March 31, 2026, compared to net income of $10.20 million, or $275.87 per
basic and diluted earnings per share, for the same period of last year. |
Fiscal Year 2026 Financial Results
Revenue
Revenue increased by $12.19 million, or 10.2%,
to $132.16 million for the fiscal year ended March 31, 2026, from $119.97 million for the same period of last
year.
Revenue from offline wholesale decreased by $0.99
million, or 0.8%, to $117.87 million for the fiscal year ended March 31, 2026, from $118.86 million for the same
period of last year. The Company previously provided credit terms to certain offline customers. However, the Company experienced delayed
repayments from several customers. Despite eventual recovery of the outstanding amounts, the Company decided to discontinue some of its
credit sales effective March 2025 as a risk mitigation measure. As a result, the offline wholesale revenue declined.
Revenue from online platform increased by $13.18
million, or 1,190.8%, to $14.29 million for the fiscal year ended March 31, 2026, from $1.11 million for the
same period of last year. This increase is primarily attributable to the inclusion of a full twelve months of Allright’s online
platform revenue in the year ended March 31, 2026, compared to only one month (March 2025) of such revenue in the prior year period. On
February 28, 2025, the Company acquired Ridgeline International Limited (“Ridgeline”) and its subsidiary, Allright, which
is a rapidly growing online and offline wholesale distributor of pharmaceutical and other healthcare products such as health foods, cosmetics
and daily necessities in China. Allright actively trades on popular online distribution platforms nationwide. Through these online platforms,
the Company sells various medical products to retail pharmacies, clinics and other vendors across the country. Allright also has its own
online distribution platform.
Gross profit and gross margin
Total cost of goods sold increased to $127.41
million for the fiscal year ended March 31, 2026, from $116.13 million for the same period of last year. Gross profit
increased by $0.92 million, or 23.8%, to $4.75 million for the fiscal year ended March 31, 2026, from $3.84
million for the same period of last year. Overall gross margin increased by 0.4 percentage points to 3.6% for the fiscal year ended March
31, 2026, from 3.2% for the same period of last year.
Gross margins for offline wholesale and online
platform were 3.4% and 5.6%, respectively, for the fiscal year ended March 31, 2026, compared to gross margins for offline wholesale
and online platform of 3.2% and 7.4%, respectively, for the same period of last year.
Loss from operations
Sales and marketing expenses increased by $1.51
million, or 98.2%, to $3.04 million for the fiscal year ended March 31, 2026, from $1.53 million for the
same period of last year. The increase was primarily attributable to the increase in drug distribution service fee resulting from the
acquisition of Allright, which was recognized over 12 months this year, compared to just one month as the acquisition took place at the
end of the fiscal year 2025. Overall, such expenses as a percentage of the Company’s revenue were 2.3% and 1.3%, respectively, for
the years ended March 31, 2026 and 2025.
General and administrative expenses increased
by $0.24 million, or 7.2%, to $3.58 million for the fiscal year ended March 31, 2026, from $3.34 million for
the same period of last year. The increase was primarily due to the increase in employee salary of approximately $0.31 million, offset
by the decrease in exchange loss. Such expenses as a percentage of revenue decreased for the year ended March 31, 2026 to 2.7% from 2.8%
for the same period a year ago. This increase in employee salary was primarily attributable to the acquisition of Ridgeline and its subsidiary
Allright on February 28, 2025, which led to a rise in employee headcount and consequently an increase in employee salaries.
Loss from operations was $1.87 million for
the fiscal year ended March 31, 2026, compared to $1.04 million for the same period of last year. Operating margin was (1.4)%
and (0.9)% for the fiscal year ended March 31, 2026 and 2025, respectively.
Net loss from continuing operations
Net loss from continuing operations was $1.25
million and $1.45 million in the years ended March 31, 2026 and 2025.
Net income (loss)
Net loss was $1.25 million, or $17.21 per
basic and diluted loss per share for the fiscal year ended March 31, 2026, compared to net income of $10.20 million, or $275.87 per
basic and diluted earnings per share for the same period of last year.
Financial Condition
As of March 31, 2026, the Company had cash
and cash equivalents of $17.91 million, compared to $12.78 million as of March 31, 2025. Net cash used in operating
activities was $1.39 million for the fiscal year ended March 31, 2026, compared to net cash provided by operating activities
of $1.25 million for the same period of last year. The change was primarily attributable to net loss of approximately $1.25
million, adjusted for non-cash item of depreciation and amortization expenses of approximately $0.36 million and changes in operating
assets and liabilities including: (i) an increase of approximately $3.46 million in accounts receivable, (ii) an increase of approximately
$2.04 million in other receivable, (iii) an increase of approximately $2.01 million in accounts payable, and (ⅳ) a decrease of approximately
$1.95 million in inventories.
Net cash used in investing activities was $449 for
the fiscal year ended March 31, 2026, compared to $18.14 million for the same period of last year. The change was primarily
attributable to $449 used for purchases of long-term assets.
Net cash used in financing activities was $0.03
million for the fiscal year ended March 31, 2026, compared to net cash provided by financing activities of $1.51 million for
the same period of last year. The change was primarily due to approximately $24.94 million in repayment of notes payable offset by approximately
$10.88 million proceeds from equity and debt financing and approximately $14.35 million in proceeds from notes payable.
About Ridgetech, Inc.
Ridgetech, Inc. (“Ridgetech” or the
“Company”) is a growing online and offline wholesale distributor of pharmaceutical and other healthcare products in China.
Ridgetech actively trades on popular online distribution platforms nationwide and has its own online distribution platform. The Company
believes that trading on these platforms offers greater opportunities to distribute pharmaceutical products nationwide. For more information
about the Company, please visit www.ridgetch.com. The Company routinely posts important information
on its website.
Forward-Looking Statements
Certain statements in this press release are
forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the
U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties
and are based on current expectations and projections about future events and financial trends that the Company believes may affect its
financial condition, results of operations, business strategy, and financial needs. These forward-looking statements include, but are
not limited to, statements concerning the Company's strategic transformation, integration of acquired businesses, development of its online
and offline pharmaceutical distribution capabilities and ecosystem, and its ability to generate long-term growth and shareholder value.
Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect,"
"anticipate," "aim," "estimate," "intend," "plan," "believe," "potential,"
"continue," "is/are likely to," or other similar expressions. The Company undertakes no obligation to update forward-looking
statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.
Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it can give no assurance
that such expectations will prove to be correct. Factors that could cause actual results or events to differ materially from those reflected
in the Company's forward-looking statements including risks related to the Company's ability to satisfy applicable procurement conditions,
changes in market demand, the Company's ability to successfully implement and promote its digital platform, and those other risks described
in the Company's most recent registration statement, most recent annual report on Form 20-F and in its other filings with the U.S. Securities
and Exchange Commission.
For more information, please contact:
Company Contact:
Frank Zhao
Interim Chief Executive Officer and Chief Financial Officer
+86-571-88077108
frank.zhao@ridgetch.com
Investor Relations Contact:
Tina Xiao
Ascent Investor Relations LLC
+1-646-932-7242
investors@ascent-ir.com
RIDGETECH, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
| | |
March 31, | | |
March 31, | |
| | |
2026 | | |
2025 | |
| ASSETS | |
| | |
| |
| CURRENT ASSETS | |
| | |
| |
| Cash and cash equivalents | |
$ | 17,905,262 | | |
$ | 12,779,781 | |
| Restricted cash | |
| 8,519 | | |
| 5,761,294 | |
| Trade accounts receivables | |
| 32,466,688 | | |
| 27,811,813 | |
| Inventories | |
| 8,259,002 | | |
| 9,758,071 | |
| Other receivables, net | |
| 5,196,109 | | |
| 2,419,671 | |
| Advances to suppliers | |
| 98,359 | | |
| 433,140 | |
| Due from related parties | |
| 329,258 | | |
| - | |
| Other current assets | |
| 292,995 | | |
| 745,477 | |
| Total current assets | |
| 64,556,192 | | |
| 59,709,247 | |
| | |
| | | |
| | |
| NON-CURRENT ASSETS | |
| | | |
| | |
| Property and equipment, net | |
| 5,723 | | |
| 8,931 | |
| Intangible assets, net | |
| 3,002,053 | | |
| 3,302,961 | |
| Goodwill | |
| 1,463,733 | | |
| 1,463,733 | |
| Total non-current assets | |
| 4,471,509 | | |
| 4,775,625 | |
| Total assets | |
$ | 69,027,701 | | |
$ | 64,484,872 | |
| | |
| | | |
| | |
| LIABILITIES AND SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| CURRENT LIABILITIES | |
| | | |
| | |
| Accounts payable | |
$ | 22,757,939 | | |
$ | 19,666,664 | |
| Notes payable | |
| 22,669 | | |
| 10,386,612 | |
| Other payables | |
| 2,752,548 | | |
| 2,319,139 | |
| Due to related parties | |
| - | | |
| 2,130 | |
| Customer deposits | |
| 364,150 | | |
| 264,068 | |
| Taxes payable | |
| 1,790,902 | | |
| 1,521,546 | |
| Accrued liabilities | |
| 206,502 | | |
| 196,210 | |
| Total current liabilities | |
| 27,894,710 | | |
| 34,356,369 | |
| | |
| | | |
| | |
| NON-CURRENT LIABILITIES | |
| | | |
| | |
| Deferred tax liabilities | |
| 356,353 | | |
| 492,121 | |
| Total non-current liabilities | |
| 356,353 | | |
| 492,121 | |
| Total liabilities | |
| 28,251,063 | | |
| 34,848,490 | |
| | |
| | | |
| | |
| COMMITMENTS AND CONTINGENCIES | |
| | | |
| | |
| SHAREHOLDERS’ EQUITY | |
| | | |
| | |
| Ordinary shares; $0.15 par value; 240,000,000 shares authorized; 887,271 and 39,033 shares issued and outstanding as of March 31, 2026 and 2025, respectively* | |
| 133,091 | | |
| 5,855 | |
| Preferred shares; $0.001 par value; 10,000,000 shares authorized; nil issued and outstanding as of March 31, 2026 and 2025 | |
| - | | |
| - | |
| Additional paid-in capital | |
| 103,898,531 | | |
| 93,142,510 | |
| Statutory reserves | |
| - | | |
| - | |
| Accumulated deficit | |
| (64,563,201 | ) | |
| (63,312,779 | ) |
| Accumulated other comprehensive income | |
| 1,308,217 | | |
| (199,204 | ) |
| Total shareholders’ equity | |
| 40,776,638 | | |
| 29,636,382 | |
| Total liabilities and shareholders’ equity | |
$ | 69,027,701 | | |
$ | 64,484,872 | |
| * | All share numbers and share amounts presented have been retroactively
adjusted to reflect the 1-for-150 reverse share split effective April 7, 2026. |
RIDGETECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE
INCOME (LOSS)
| | |
For the years ended
March 31, | |
| | |
2026 | | |
2025 | | |
2024 | |
| REVENUES, NET | |
$ | 132,163,734 | | |
$ | 119,971,638 | | |
$ | 123,994,053 | |
| | |
| | | |
| | | |
| | |
| COST OF GOODS SOLD | |
| 127,409,588 | | |
| 116,132,823 | | |
| 119,115,636 | |
| | |
| | | |
| | | |
| | |
| GROSS PROFIT | |
| 4,754,146 | | |
| 3,838,815 | | |
| 4,878,417 | |
| | |
| | | |
| | | |
| | |
| SELLING EXPENSES | |
| 3,040,136 | | |
| 1,534,200 | | |
| 934,223 | |
| GENERAL AND ADMINISTRATIVE EXPENSES | |
| 3,580,025 | | |
| 3,339,954 | | |
| 3,348,112 | |
| TOTAL OPERATING EXPENSES | |
| 6,620,161 | | |
| 4,874,154 | | |
| 4,282,335 | |
| | |
| | | |
| | | |
| | |
| INCOME (LOSS) FROM OPERATIONS | |
| (1,866,015 | ) | |
| (1,035,339 | ) | |
| 596,082 | |
| | |
| | | |
| | | |
| | |
| OTHER INCOME (EXPENSES): | |
| | | |
| | | |
| | |
| INTEREST INCOME | |
| 455,061 | | |
| 92,834 | | |
| 197,763 | |
| INTEREST EXPENSES | |
| (67,069 | ) | |
| - | | |
| - | |
| INVESTMENT INCOME (EXPENSES) | |
| 229,657 | | |
| - | | |
| (1,607,537 | ) |
| OTHER INCOME (EXPENSES) | |
| (101,154 | ) | |
| (8,155 | ) | |
| (13,377 | ) |
| TOTAL OF OTHER INCOME (EXPENSES) | |
| 516,495 | | |
| 84,679 | | |
| (1,423,151 | ) |
| | |
| | | |
| | | |
| | |
| LOSS BEFORE INCOME TAXES | |
| (1,349,520 | ) | |
| (950,660 | ) | |
| (827,069 | ) |
| | |
| | | |
| | | |
| | |
| (BENEFIT) PROVISION FOR INCOME TAXES | |
| (99,098 | ) | |
| 503,524 | | |
| (41,363 | ) |
| NET LOSS FROM CONTINUING OPERATIONS | |
| (1,250,422 | ) | |
| (1,454,184 | ) | |
| (785,706 | ) |
| NET LOSS FROM DISCONTINUED OPERATIONS, NET OF TAXES | |
| - | | |
| (4,103,718 | ) | |
| (3,448,536 | ) |
| GAIN OF DIVESTITURE JIUXIN INVESTMENT | |
| - | | |
| 15,757,753 | | |
| - | |
| NET GAIN(LOSS) FROM DISCONTINUED OPERATIONS, NET OF TAX | |
| - | | |
| 11,654,035 | | |
| (3,448,536 | ) |
| | |
| | | |
| | | |
| | |
| NET (LOSS) INCOME | |
| (1,250,422 | ) | |
| 10,199,851 | | |
| (4,234,242 | ) |
| | |
| | | |
| | | |
| | |
| LESS: NET LOSS ATTRIBUTABLE TO NONCONTROLLING INTEREST | |
| - | | |
| 5,384 | | |
| (14 | ) |
| | |
| | | |
| | | |
| | |
| NET (LOSS) INCOME ATTRIBUTABLE TO RIDGETECH, INC. | |
| (1,250,422 | ) | |
| 10,194,467 | | |
| (4,234,228 | ) |
| NET (LOSS) INCOME ATTRIBUTABLE TO RIDGETECH, INC. FROM CONTINUING OPERATIONS | |
| (1,250,422 | ) | |
| (1,454,184 | ) | |
| (785,706 | ) |
| NET (LOSS) INCOME ATTRIBUTABLE TO RIDGETECH, INC. FROM DISCONTINUED OPERATIONS | |
| - | | |
| 11,648,651 | | |
| (3,448,522 | ) |
| | |
| | | |
| | | |
| | |
| OTHER COMPREHENSIVE INCOME (LOSS) | |
| | | |
| | | |
| | |
| FOREIGN CURRENCY TRANSLATION ADJUSTMENTS | |
| 1,507,421 | | |
| (1,204,966 | ) | |
| (729,373 | ) |
| COMPREHENSIVE INCOME (LOSS) | |
| 256,999 | | |
| 8,994,885 | | |
| (4,963,615 | ) |
| | |
| | | |
| | | |
| | |
| WEIGHTED AVERAGE NUMBER OF SHARES*: | |
| | | |
| | | |
| | |
| Basic | |
| 72,668 | | |
| 36,954 | | |
| 9,628 | |
| Diluted | |
| 72,668 | | |
| 36,954 | | |
| 9,628 | |
| | |
| | | |
| | | |
| | |
| (LOSS) INCOME PER SHARE*: | |
| | | |
| | | |
| | |
| Basic | |
$ | (17.21 | ) | |
$ | 275.87 | | |
$ | (439.78 | ) |
| Diluted | |
$ | (17.21 | ) | |
$ | 275.87 | | |
$ | (439.78 | ) |
| * | All share and per-share amounts presented have been retroactively
adjusted to reflect the 1-for-150 reverse share split effective April 7, 2026. |
RIDGETECH, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
| | |
For the years ended
March 31, | |
| | |
2026 | | |
2025 | | |
2024 | |
| CASH FLOWS FROM OPERATING ACTIVITIES: | |
| | |
| | |
| |
| Net (loss) income | |
$ | (1,250,422 | ) | |
$ | 10,199,851 | | |
$ | (4,234,242 | ) |
| Adjustments to reconcile net (loss) income to net cash used in operating activities: | |
| | | |
| | | |
| | |
| Depreciation and amortization | |
| 363,686 | | |
| 1,137,240 | | |
| 790,449 | |
| Provision for (reversal of) doubtful accounts | |
| (428,420 | ) | |
| 85,642 | | |
| (249,257 | ) |
| Amortization of right-of-use assets | |
| - | | |
| 4,879,012 | | |
| 4,594,172 | |
| Loss from disposal of property and equipment | |
| - | | |
| - | | |
| 107,251 | |
| Gain of divestiture Jiuxin Investment | |
| - | | |
| (15,757,753 | ) | |
| - | |
| Deferred tax expenses(benefits) | |
| (79,692 | ) | |
| (29,822 | ) | |
| - | |
| Investment loss | |
| - | | |
| - | | |
| 1,607,537 | |
| Change in operating assets and liabilities: | |
| | | |
| | | |
| | |
| Accounts receivable | |
| (3,461,596 | ) | |
| 10,040,414 | | |
| (1,804,440 | ) |
| Notes receivable | |
| 29,743 | | |
| (29,271 | ) | |
| 19,943 | |
| Inventories and biological assets | |
| 1,948,887 | | |
| 405,822 | | |
| (1,699,621 | ) |
| Other receivables | |
| (2,042,206 | ) | |
| (11,758,658 | ) | |
| (672,830 | ) |
| Advances to suppliers | |
| 449,647 | | |
| (341,702 | ) | |
| (839,221 | ) |
| Long term deposit | |
| - | | |
| (1,361,613 | ) | |
| (132,568 | ) |
| Other current assets | |
| 477,144 | | |
| - | | |
| 19,076 | |
| Other noncurrent assets | |
| - | | |
| (359,114 | ) | |
| 69,539 | |
| Amount due from related parties | |
| - | | |
| - | | |
| (317,828 | ) |
| Accounts payable | |
| 2,009,206 | | |
| (21,128,762 | ) | |
| 6,002,186 | |
| Other payables and accrued liabilities | |
| 321,435 | | |
| 28,752,570 | | |
| 868,975 | |
| Customer deposits | |
| 83,870 | | |
| (162,940 | ) | |
| (144,761 | ) |
| Taxes payable | |
| 184,773 | | |
| 1,314,644 | | |
| (948,277 | ) |
| Operating lease liabilities | |
| - | | |
| (4,637,790 | ) | |
| (6,191,522 | ) |
| Net cash provided by (used in) operating activities | |
| (1,393,945 | ) | |
| 1,247,770 | | |
| (3,155,439 | ) |
| | |
| | | |
| | | |
| | |
| CASH FLOWS FROM INVESTING ACTIVITIES: | |
| | | |
| | | |
| | |
| Acquisition of equipment and building | |
| (449 | ) | |
| (155,360 | ) | |
| (330,677 | ) |
| Investment in a joint venture | |
| - | | |
| - | | |
| (1,116,212 | ) |
| Purchases of intangible assets | |
| - | | |
| - | | |
| (66,973 | ) |
| Additions to leasehold improvements | |
| - | | |
| (459,907 | ) | |
| (525,988 | ) |
| Acquisition of Ridgeline, net of cash acquired | |
| - | | |
| 4,833,439 | | |
| - | |
| Divestiture Jiuxin Investment, net of cash disposed | |
| - | | |
| (22,353,250 | ) | |
| - | |
| Net cash used in investing activities | |
| (449 | ) | |
| (18,135,078 | ) | |
| (2,039,850 | ) |
| | |
| | | |
| | | |
| | |
| CASH FLOWS FROM FINANCING ACTIVITIES: | |
| | | |
| | | |
| | |
| Proceeds from short-term bank loan | |
| - | | |
| - | | |
| 1,116,212 | |
| Repayment of short-term bank loan | |
| - | | |
| (277,266 | ) | |
| (837,159 | ) |
| Proceeds from notes payable | |
| 14,353,624 | | |
| 51,689,531 | | |
| 56,875,403 | |
| Repayment of notes payable | |
| (24,944,614 | ) | |
| (56,365,693 | ) | |
| (52,997,171 | ) |
| Net proceeds from issuance of shares and warrants in private placements | |
| 10,883,257 | | |
| 7,633,000 | | |
| 2,589,600 | |
| Proceeds from other payable-related parties | |
| - | | |
| 325,784 | | |
| 1,257,406 | |
| Repayment of other payable-related parties | |
| (321,981 | ) | |
| (1,499,764 | ) | |
| - | |
| Net cash provided by (used in) financing activities | |
| (29,714 | ) | |
| 1,505,592 | | |
| 8,004,291 | |
| | |
| | | |
| | | |
| | |
| EFFECT OF EXCHANGE RATE ON CASH | |
| 796,814 | | |
| 1,048,620 | | |
| (1,505,475 | ) |
| | |
| | | |
| | | |
| | |
| (DECREASE) INCREASE I IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH | |
| (627,294 | ) | |
| (14,333,096 | ) | |
| 1,303,527 | |
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of year | |
| 18,541,075 | | |
| 32,874,171 | | |
| 31,570,644 | |
| CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of year | |
$ | 17,913,781 | | |
$ | 18,541,075 | | |
$ | 32,874,171 | |
| | |
| | | |
| | | |
| | |
| SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION: | |
| | | |
| | | |
| | |
| Cash paid for income taxes | |
$ | 55,348 | | |
$ | 137,456 | | |
$ | 149,023 | |
| Cash paid for interest | |
| 67,069 | | |
| 6,289 | | |
| 13,604 | |
| | |
| | | |
| | | |
| | |
| NON-CASH ACTIVITIES： | |
| | | |
| | | |
| | |
| Cashless exercise of warrants | |
$ | 51,671 | | |
$ | - | | |
$ | - | |
| Issuance of shares for acquisition of subsidiaries | |
| - | | |
| 3,582,250 | | |
| - | |
| Cancellation of shares for disposal of subsidiaries | |
| - | | |
| 4,102,848 | | |
| - | |
| Subscription receivable from issuance of ordinary shares | |
| 3,791,077 | | |
| - | | |
| - | |
| (a) |
The cash flows related to discontinued operations have not been segregated. Accordingly, the Consolidated Statements of Cash Flows include the results of continuing and discontinued operations. |
7
